Androgens and osteoporosis

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 3, 2010, Pages 284-292

  Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bone modeling; Bone remodelling; Oestradiol; Osteoporosis in men; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SEX HORMONE; TESTOSTERONE; VITAMIN D;

AGING; ANDROGEN DEFICIENCY; AROMATIZATION; BONE CELL; BONE GROWTH; BONE REMODELING; CROSS-SECTIONAL STUDY; FRACTURE; HISTORY; HUMAN; LONGITUDINAL STUDY; MASS SPECTROMETRY; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PERIOSTEUM; REVIEW; RISK;

ANDROGENS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; ORCHIECTOMY; OSTEOPOROSIS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 77951810785     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328339658c     Document Type: Review

References (76)

1. Ebeling PR. Clinical practice. Osteoporosis in men. New Engl J Med 2008; 358:1474-1482.
2. Jiang HX, Majumdar SR, Dick DA, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005; 20:494-500.
3. Chang KP, Center JR, Nguyen TV, Eisman JA. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2004; 19:532-536.
4. Jones G, White C, Nguyen T, et al. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996; 6:233-239.
5. O'Neill T, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11:1010-1018.
6. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7:221-227.
7. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. J Am Med Assoc 2009; 301:513-521.
8. Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15:551-555.
9. Seeman E, Bianchi G, Khosla S, et al. Bone fragility in men: where are we? Osteoporos Int 2006; 17:1577-1583.
10. Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging 1998; 13:421-434; 9.
11. Abbasi AA, Rudman D, Wilson CR, et al. Observations on nursing home patients with a history of hip fracture. Am J Med Sci 1995; 310:229-234.
12. Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 2008; 23:143-150.
13. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056-1061.
14. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689-3698.
15. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004; 25:389-425.
16. Vanderschueren D, Venken K, Ophoff J, et al. Clinical review: sex steroids and the periosteum: reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab 2006; 91:378-382.
17. Erbas E, Ristevski S, Poon C, et al. Decreased spinal and femoral neck volumetric bone mineral density (BMD) in men with primary osteoporosis and their first degree male relatives: familial effect on BMD in men. Clin Endocrinol 2007; 66:78-84.
18. Szulc P, Delmans PD. Biochemical markers of bone turnover in men. Calcif Tissue Int 2001; 69:229-234.
19. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91:3908-3915.
20. Khosla S, Riggs BL, Atkinson EJ, et al. Effects on sex and age on bone microstructure at the ultradistal radius: a population based noninvasive in vivo assessment. J Bone Mineral Res 2006; 21:124-131.
21. Riggs BL, Melton LJ, Robb RA, et al. A population based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2007. [Epub ahead of print]
22. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
23. Kasperk C, Helmboldt A, Borcsok I, et al. Skeletal site-dependent expression of the androgen receptor in human osteoblastic cell populations. Calcif Tissue Int 1997; 61:464-473.
24. Onoe Y, Miyaura C, Ohta H, et al. Expression of estrogen receptor b in rat bone. Endocrinology 1997; 138:4509-4512.
25. Arts J, Kuiper GG, Janssen JM, et al. Differential expression of estrogen receptors a and b mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 1997; 138:5067-5070.
26. Abu EO, Horner A, Kusec V, et al. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997; 82:3493-3497. (Pubitemid 27419110)
27. Pederson L, Kremer M, Judd J, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci (USA) 1999; 96:505-510.
28. Callewaert F, Boonen S, Vanderschueren D. Sex steroids and the male skeleton: a tale of two hormones. Trends Endocrinol Metab 2009 [Epub ahead of print].
29. Huber DM, Bendixen AC, Pathrose P, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001; 142:3800-3808.
30. Sims NA, Brennan K, Spaliviero J, et al. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab 2006; 290:E456-E462.
31. Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990; 8:612-617.
32. Vandenput L, Boonen S, Van Herck E, et al. Evidence from the aged orchidectomized male rat model that 17b-estradiol is a more effective bone-sparing and anabolic agent than 5a-dihydrotestosterone. J Bone Miner Res 2002; 17:2080-2086.
33. Vandenput L, Swinnen JV, Van Herck E, et al. The estrogen receptor ligand ICI 182,780 does not impair the bone-sparing effects of testosterone in the young orchidectomized rat model. Calcif Tissue Int 2002; 70:170-175.
34. Munoz-Torres M, Jodar E, Quesada M, Escobar-Jimenez F. Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Calcif Tissue Int 1995; 57:94-96.
35. Bertelloni S, Baroncelli GI, Federico G, et al. Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 1998; 50:309-314.
36. Notini AJ, Davey RA, McManus JF, et al. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 2005; 35:547-555.
37. Chiang C, Chiu M, Moore AJ, et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res 2009; 24:621-631.
38. Finkelstein JS, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326:600-604.
39. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996; 81:1152-1155. (Pubitemid 26083985)
40. Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106: 354-361.
41. Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 2005; 20:1334-1341.
42. Clarke BL, Ebeling PR, Jones JD, et al. Changes in quantitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab 1996; 81:2264-2270.
43. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106:1553-1560.
44. Leder BZ, LeBlanc KM, Schoenfeld DA, et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88:204-210.
45. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009; 94:4785-4792.
46. Khosla S, Melton LJ III, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83:2266-2274.
47. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res 1997; 12:1833-1843. (Pubitemid 27500195)
48. Sartorius G, Ly LP, Sikaris K, et al. Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem 2009; 46 (Pt 2):137-143.
49. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab 2006; 91:1336-1344.
50. Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing 1992; 21:139-141.
51. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991; 39:766-771.
52. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85: 219-223.
53. Mellstrom D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21:529-535.
54. Bjornerem A, Ahmed LA, Joakimsen RM, et al. A prospective study of sex steroids, sex hormone-binding globulin, and nonvertebral fractures in women and men: The Tromso Study. Eur J Endocrinol 2007; 157:119-125.
55. Goderie-Plomp HW, van der Klift M, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: The Rotterdam Study. J Clin Endocrinol Metab 2004; 89:3261-3269.
56. Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119:426-433.
57. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86:3555-3561.
58. Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men. Arch Intern Med 2008; 168:47-54.
59. Mellström D, Vandenput L, Mallmin H, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23:1552-1560.
60. LeBlanc ES, Nielson CM, Marshall LM, et al., Osteoporotic Fractures in Men Study Group. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 2009; 94:3337-3346.
61. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta analysis. Lancet 2007; 370:657-666.
62. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73:288-294.
63. Behre HM, Kliesch S, Leifke E, et al. Longterm effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386-2390.
64. Leifke E, Kö rner HC, Link TM, et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998; 138:51-58.
65. Aminorroaya A, Kelleher S, Conway AJ, et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152:881-886.
66. Finklestein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 1989; 69:776-783.
67. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510.
68. Benito M, Vasilic B, Wehrli FW, et al. Effects of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 2005; 20:1785-1791.
69. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90:1502-1510.
70. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972. (Pubitemid 30647018)
71. Anderson F, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 1996; 18:171-177.
72. Anderson F, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997; 12:472-478.
73. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610.
74. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26:427-431.
75. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9-17.
76. Kaufman J-M, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16:510-516.